

# Emmanuel J Favaloro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3402528/publications.pdf>

Version: 2024-02-01

692  
papers

21,839  
citations

20759

60  
h-index

22102

113  
g-index

703  
all docs

703  
docs citations

703  
times ranked

17021  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
2	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2103-2114.	1.9	1,061
3	D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 876-878.	1.8	474
4	Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. <i>Clinica Chimica Acta</i> , 2020, 507, 167-173.	0.5	301
5	Clinical Utility of the PFA-100. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 709-733.	1.5	285
6	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2018, 118, 437-450.	1.8	268
7	Characterization of GMP-140 (P-selectin) as a circulating plasma protein.. <i>Journal of Experimental Medicine</i> , 1992, 175, 1147-1150.	4.2	258
8	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	1.9	211
9	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
10	The paradoxical relationship between serum uric acid and cardiovascular disease. <i>Clinica Chimica Acta</i> , 2008, 392, 1-7.	0.5	191
11	Clinical application of the PFA-100 <sup>®</sup> . <i>Current Opinion in Hematology</i> , 2002, 9, 407-415.	1.2	165
12	International consensus guidelines on anticardiolipin and anti- $\beta_2$ -glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies. <i>Arthritis and Rheumatism</i> , 2012, 64, 1-10.	6.7	163
13	Quality Standards for Sample Collection in Coagulation Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 565-575.	1.5	156
14	Preanalytical and Postanalytical Variables: The Leading Causes of Diagnostic Error in Hemostasis?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 612-634.	1.5	153
15	Moderate Red Wine Consumption and Cardiovascular Disease Risk: Beyond the "French Paradox". <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 059-070.	1.5	151
16	Mental Depression and Cardiovascular Disease: A Multifaceted, Bidirectional Association. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 325-336.	1.5	133
17	"Criteria"™ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. <i>Lupus</i> , 2011, 20, 182-190.	0.8	122
18	ABO blood group, hypercoagulability, and cardiovascular and cancer risk. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 137-149.	2.7	117

#	ARTICLE	IF	CITATIONS
19	Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 576-585.	1.5	112
20	Aging Hemostasis: Changes to Laboratory Markers of Hemostasis As We Age—A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 621-633.	1.5	112
21	Obstructive Sleep Apnea Syndrome and Cardiovascular Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 280-297.	1.5	109
22	Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. <i>Haemophilia</i> , 2001, 7, 170-179.	1.0	108
23	Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis. <i>Laboratory Medicine</i> , 2012, 43, 1.2-10.	0.8	103
24	Interference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 258-266.	1.5	101
25	Thrombotic Complications of Erythropoiesis-Stimulating Agents. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 537-549.	1.5	100
26	von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 440-455.	1.5	99
27	Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 208-227.	1.5	95
28	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1008-1020.	1.8	94
29	Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1191-1199.	1.4	94
30	Mild hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 421-432.	1.9	92
31	Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand's disease. <i>Blood Coagulation and Fibrinolysis</i> , 1991, 2, 285-292.	0.5	90
32	Assessing the Usefulness of Anticardiolipin Antibody Assays. <i>American Journal of Clinical Pathology</i> , 2002, 118, 548-557.	0.4	90
33	Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder. <i>American Journal of Clinical Pathology</i> , 2005, 124, 910-917.	0.4	90
34	Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 459-471.	1.0	90
35	The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. <i>Pathology</i> , 2016, 48, 60-71.	0.3	90
36	A Diet Rich in High-Oleic-Acid Sunflower Oil Favorably Alters Low-Density Lipoprotein Cholesterol, Triglycerides, and Factor VII Coagulant Activity. <i>Journal of the American Dietetic Association</i> , 2005, 105, 1071-1079.	1.3	87

#	ARTICLE	IF	CITATIONS
37	An Update on the von Willebrand Factor Collagen Binding Assay: 21 Years of Age and Beyond Adolescence but Not Yet a Mature Adult. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 727-744.	1.5	86
38	Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 433-446.	1.5	86
39	Factor V inhibitors. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 637-647.	0.5	85
40	Laboratory Investigation of Thrombophilia: The Good, the Bad, and the Ugly. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 695-710.	1.5	85
41	The role of ethnicity, age and gender in venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 489-496.	1.0	85
42	Contemporary platelet function testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 579-598.	1.4	84
43	Coronavirus Disease 2019—Associated Coagulopathy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 203-217.	1.4	84
44	MUTATIONS IN A SUBGROUP OF PATIENTS WITH MILD HAEMOPHILIA A AND A FAMILIAL DISCREPANCY BETWEEN THE ONE-STAGE AND TWO-STAGE FACTOR VIII:C METHODS. <i>British Journal of Haematology</i> , 1996, 94, 400-406.	1.2	82
45	Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing. <i>American Journal of Clinical Pathology</i> , 2004, 122, 686-692.	0.4	82
46	Help me, Doctor! My D-dimer is raised. <i>Annals of Medicine</i> , 2008, 40, 594-605.	1.5	81
47	Laboratory tests used to help diagnose von Willebrand disease: an update. <i>Pathology</i> , 2016, 48, 303-318.	0.3	81
48	Laboratory Identification of von Willebrand Disease: Technical and Scientific Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 456-471.	1.5	80
49	Laboratory testing of anticoagulants: the present and the future. <i>Pathology</i> , 2011, 43, 682-692.	0.3	80
50	Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 185-97.	1.4	80
51	Activated Partial Thromboplastin Time: New Tricks for an Old Dogma. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 604-611.	1.5	77
52	Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 400-418.	1.5	75
53	Use of a novel platelet function analyzer (PFA-100?) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders. , 1999, 62, 165-174.		73
54	Venous and Arterial Thromboses: Two Sides of the Same Coin?. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 239-248.	1.5	73

#	ARTICLE	IF	CITATIONS
55	The Utility of the PFA-100 in the Identification of von Willebrand Disease: A Concise Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 537-545.	1.5	72
56	Clinical utility of closure times using the platelet function analyzerâ€100/200. <i>American Journal of Hematology</i> , 2017, 92, 398-404.	2.0	70
57	Phenotypic Identification of Platelet-Type von Willebrand Disease and Its Discrimination from Type 2B von Willebrand Disease: A Question of 2B or Not 2B? A Story of Nonidentical Twins? Or Two Sides of a Multidenominational or Multifaceted Primary-Hemostasis Coin?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 113-127.	1.5	69
58	Evaluating errors in the laboratory identification of von Willebrand disease in the real world. <i>Thrombosis Research</i> , 2014, 134, 393-403.	0.8	68
59	Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. <i>Annals of Translational Medicine</i> , 2017, 5, 322-322.	0.7	68
60	Identification of factor inhibitors by diagnostic haemostasis laboratories. <i>Thrombosis and Haemostasis</i> , 2006, 96, 73-78.	1.8	66
61	Laboratory testing for suspected COVIDâ€19 vaccineâ€induced (immune) thrombotic thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 559-570.	0.7	66
62	Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. <i>Blood</i> , 2000, 95, 164-172.	0.6	65
63	Laboratory Assessment of von Willebrand Factor: Use of Different Assays Can Influence the Diagnosis of von Willebrandâ€™s Disease, Dependent on Differing Sensitivity to Sample Preparation and Differential Recognition of High Molecular Weight VWF Forms. <i>American Journal of Clinical Pathology</i> , 1995, 104, 264-271.	0.4	64
64	The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. <i>Pathology</i> , 2015, 47, 355-364.	0.3	64
65	Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 379-382.	1.5	64
66	How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 022-035.	1.5	63
67	Therapeutic monitoring of unfractionated heparin â€ trials and tribulations. <i>Expert Review of Hematology</i> , 2017, 10, 595-605.	1.0	61
68	Reducing Errors in Identification of von Willebrand Disease: The Experience of the Royal College of Pathologists of Australasia Quality Assurance Program. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 505-513.	1.5	60
69	Milestones and Perspectives in Coagulation and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 009-022.	1.5	60
70	Internal Quality Control and External Quality Assurance of Platelet Function Tests. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 139-149.	1.5	60
71	Laboratory Testing in Disseminated Intravascular Coagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 458-467.	1.5	60
72	von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey. <i>Seminars in Thrombosis and Hemostasis</i> , 2002, 28, 191-202.	1.5	59

#	ARTICLE	IF	CITATIONS
73	The LOC387715 Polymorphism, Inflammatory Markers, Smoking, and Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2008, 115, 693-699.	2.5	59
74	Laboratory Testing and Identification of Antiphospholipid Antibodies and the Antiphospholipid Syndrome: A Potpourri of Problems, a Compilation of Possible Solutions. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 389-410.	1.5	59
75	Treatment of von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 133-146.	1.5	59
76	Differential expression of surface antigens on activated endothelium. <i>Immunology and Cell Biology</i> , 1993, 71, 571-581.	1.0	58
77	Standards and reference materials for the anticardiolipin and anti-Î²2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Clinica Chimica Acta</i> , 2012, 413, 358-360.	0.5	58
78	Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. <i>Pathology</i> , 2014, 46, 481-495.	0.3	58
79	Towards improved diagnosis of von Willebrand disease: Comparative evaluations of several automated von Willebrand factor antigen and activity assays. <i>Thrombosis Research</i> , 2014, 134, 1292-1300.	0.8	57
80	International Survey on D-Dimer Test Reporting: A Call for Standardization. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 287-293.	1.5	57
81	Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. <i>Thrombosis Research</i> , 2016, 141, 202-211.	0.8	57
82	Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. <i>Blood Reviews</i> , 1999, 13, 185-204.	2.8	56
83	Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and vWF:CBA as combined diagnostic strategies. <i>Haemophilia</i> , 2001, 7, 180-189.	1.0	56
84	Consensus guidelines on anti-cardiolipin antibody testing and reporting. <i>Pathology</i> , 2004, 36, 63-68.	0.3	56
85	Prevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 237-251.	1.5	56
86	Harmonisation of D-dimer " A call for action. <i>Thrombosis Research</i> , 2016, 137, 219-220.	0.8	56
87	A Multilaboratory Peer Assessment Quality Assurance Program-Based Evaluation of Anticardiolipin Antibody, and beta2-Glycoprotein I Antibody Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 73-84.	1.5	55
88	von Willebrand's disease: Use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. <i>American Journal of Hematology</i> , 1994, 45, 205-211.	2.0	54
89	Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part I " Anticardiolipin and Anti-Î²2-Glycoprotein I Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 390-403.	1.5	54
90	Shortened activated partial thromboplastin time: causes and management. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 459-463.	0.5	53

#	ARTICLE	IF	CITATIONS
91	Acquired Inhibitors of Coagulation Factors: Part II. Seminars in Thrombosis and Hemostasis, 2012, 38, 447-453.	1.5	53
92	Co-expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis. British Journal of Haematology, 1990, 74, 385-394.	1.2	52
93	Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thrombosis and Haemostasis, 2010, 104, 1009-1021.	1.8	52
94	Frequency of Platelet type versus Type 2B von Willebrand Disease. Thrombosis and Haemostasis, 2011, 105, 501-508.	1.8	52
95	Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part II "Lupus Anticoagulant. Seminars in Thrombosis and Hemostasis, 2012, 38, 404-411.	1.5	52
96	Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagulation and Fibrinolysis, 2006, 17, 39-45.	0.5	50
97	Measuring the Quality of Journals and Journal Articles: The Impact Factor Tells but a Portion of the Story. Seminars in Thrombosis and Hemostasis, 2008, 34, 007-025.	1.5	50
98	Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagulation and Fibrinolysis, 2005, 16, 597-605.	0.5	49
99	C-reactive protein and venous thromboembolism: causal or casual association?. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1693-1701.	1.4	49
100	E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism. Seminars in Thrombosis and Hemostasis, 2014, 40, 060-065.	1.5	49
101	D-Dimer Testing: Laboratory Aspects and Current Issues. Methods in Molecular Biology, 2017, 1646, 91-104.	0.4	49
102	ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. International Journal of Laboratory Hematology, 2021, 43, 129-136.	0.7	49
103	The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2408-2411.	1.9	49
104	Circulating Inflammatory Markers and Hemostatic Factors in Age-Related Maculopathy: A Population-Based Case-Control Study. , 2007, 48, 1983.		48
105	Standardization of the INR: How Good Is Your Laboratory's INR and Can It Be Improved?. Seminars in Thrombosis and Hemostasis, 2008, 34, 593-603.	1.5	48
106	Differential sensitivity of von Willebrand factor (VWF) activity assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. Journal of Thrombosis and Haemostasis, 2012, 10, 1043-1054.	1.9	48
107	Genetic testing for von Willebrand disease: the case against. Journal of Thrombosis and Haemostasis, 2010, 8, 6-12.	1.9	47
108	Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research, 2019, 180, 10-19.	0.8	47

#	ARTICLE	IF	CITATIONS
109	Multilaboratory Testing of Thrombophilia: Current and Past Practice in Australasia as Assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 49-58.	1.5	46
110	Glanzmann thrombasthenia: An update. <i>Clinica Chimica Acta</i> , 2010, 411, 1-6.	0.5	46
111	Inherited and acquired factor V deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 160-166.	0.5	46
112	Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. <i>Pathology</i> , 2019, 51, 292-300.	0.3	46
113	Laboratory assays for von Willebrand Factor: relative contribution to the diagnosis of von Willebrand's disease. <i>Pathology</i> , 1997, 29, 385-391.	0.3	45
114	A laboratory evaluation into the short activated partial thromboplastin time. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 152-157.	0.5	45
115	Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring?. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 756-765.	1.5	45
116	The new oral anticoagulants and the future of haemostasis laboratory testing. <i>Biochemia Medica</i> , 2012, 22, 329-341.	1.2	45
117	Diagnosis and classification of von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 553-564.	0.5	44
118	Diagnosing von Willebrand Disease: A Short History of Laboratory Milestones and Innovations, Plus Current Status, Challenges, and Solutions. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 551-570.	1.5	44
119	Current and Emerging Direct Oral Anticoagulants: State-of-the-Art. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 490-501.	1.5	44
120	COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 072-092.	1.5	44
121	Von willebrand's disease: laboratory investigation using an improved functional assay for von willebrand factor. <i>Pathology</i> , 1993, 25, 152-158.	0.3	44
122	Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD11b, CD13 and CD33. <i>British Journal of Haematology</i> , 1988, 69, 163-171.	1.2	43
123	Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). <i>International Journal of Laboratory Hematology</i> , 2021, 43, 21-28.	0.7	43
124	Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges. <i>Current Drug Metabolism</i> , 2017, 18, 598-608.	0.7	43
125	Development of Consensus Guidelines for Anticardiolipin and Lupus Anticoagulant Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 39-48.	1.5	42
126	Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 616-8.	1.4	42



#	ARTICLE	IF	CITATIONS
127	Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2828-2831.	1.9	42
128	Hemostatic Properties of the Lymph: Relationships with Occlusion and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 213-221.	1.5	42
129	Laboratory identification of factor inhibitors: an update. <i>Pathology</i> , 2012, 44, 293-302.	0.3	42
130	Updates on improvement of human athletic performance: focus on world records in athletics. <i>British Medical Bulletin</i> , 2008, 87, 7-15.	2.7	41
131	Epidemiological association between fasting plasma glucose and shortened APTT. <i>Clinical Biochemistry</i> , 2009, 42, 118-120.	0.8	41
132	Overview of Hemostasis and Thrombosis and Contribution of Laboratory Testing to Diagnosis and Management of Hemostasis and Thrombosis Disorders. <i>Methods in Molecular Biology</i> , 2017, 1646, 3-27.	0.4	41
133	Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 845-849.	1.5	41
134	2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. <i>Thrombosis and Haemostasis</i> , 2007, 98, 346-358.	1.8	40
135	Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. <i>British Journal of Haematology</i> , 2007, 139, 623-626.	1.2	40
136	Patient Safety and Quality in Laboratory and Hemostasis Testing: A Renewed Loop?. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 553-558.	1.5	40
137	Detection of von Willebrand Disorder and Identification of Qualitative von Willebrand Factor Defects. <i>American Journal of Clinical Pathology</i> , 2000, 114, 608-618.	0.4	39
138	The Bidirectional Relationship of Cancer and Hemostasis and the Potential Role of Anticoagulant Therapy in Moderating Thrombosis and Cancer Spread. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 644-653.	1.5	39
139	Problems and Solutions in Laboratory Testing for Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 816-833.	1.5	39
140	Platelet Function Analyzed by Light Transmission Aggregometry. <i>Methods in Molecular Biology</i> , 2017, 1646, 321-331.	0.4	39
141	Direct-to-consumer testing: more risks than opportunities. <i>International Journal of Clinical Practice</i> , 2011, 65, 1221-1229.	0.8	38
142	Type 2M von Willebrand disease “ more often misidentified than correctly identified. <i>Haemophilia</i> , 2016, 22, e145-55.	1.0	38
143	Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update. <i>Pathology</i> , 2017, 49, 346-355.	0.3	38
144	A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. <i>Pathology</i> , 2004, 36, 182-192.	0.3	37

#	ARTICLE	IF	CITATIONS
145	Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. <i>Pathology</i> , 2007, 39, 504-511.	0.3	37
146	Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. <i>Biomarkers in Medicine</i> , 2011, 5, 63-70.	0.6	37
147	Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. <i>Methods in Molecular Biology</i> , 2017, 1646, 473-494.	0.4	37
148	Comparison of the effects of two low fat diets with different $\hat{\omega}$ -linolenic:linoleic acid ratios on coagulation and fibrinolysis. <i>Atherosclerosis</i> , 1999, 142, 159-168.	0.4	36
149	Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. <i>Pathology</i> , 1999, 31, 142-147.	0.3	36
150	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. <i>Thrombosis and Haemostasis</i> , 2007, 97, 922-930.	1.8	36
151	Unsuspected Triggers of Venous Thromboembolism – Trivial or Not So Trivial?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 597-604.	1.5	36
152	Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCO) von Willebrand factor activity assays?. <i>Thrombosis Research</i> , 2009, 123, 862-868.	0.8	36
153	Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 515-532.	1.5	36
154	Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease. <i>American Journal of Hematology</i> , 2017, 92, 114-118.	2.0	36
155	Sudden Cardiac and Noncardiac Death in Sports: Epidemiology, Causes, Pathogenesis, and Prevention. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 780-786.	1.5	36
156	The role of buffer anions and protons in secretion by the rabbit mandibular salivary gland.. <i>Journal of Physiology</i> , 1982, 322, 273-286.	1.3	35
157	Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 295-304.	1.5	35
158	Toward a New Paradigm for the Identification and Functional Characterization of von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 060-075.	1.5	35
159	Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 132-138.	0.7	35
160	Type 2M and Type 2A von Willebrand Disease: Similar but Different. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 483-497.	1.5	35
161	Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 264-274.	1.5	35
162	Heparin - induced thrombocytopenia: laboratory investigation and confirmation of diagnosis. <i>Pathology</i> , 1992, 24, 177-183.	0.3	35

#	ARTICLE	IF	CITATIONS
163	Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. <i>Pathology</i> , 2008, 40, 58-63.	0.3	34
164	Genetics of type 2B von Willebrand Disease: "True 2B," "tricky 2B," or "Not 2B." What Are the Modifiers of the Phenotype?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 520-531.	1.5	34
165	Regulation in Hemostasis and Thrombosis: Part I "In Vitro Diagnostics. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 235-249.	1.5	34
166	Preanalytical Issues in Hemostasis and Thrombosis Testing. <i>Methods in Molecular Biology</i> , 2017, 1646, 29-42.	0.4	34
167	HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia. <i>Pathology</i> , 2018, 50, 426-436.	0.3	34
168	The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 41-48.	0.7	34
169	Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2008, 21, 178-83.	0.1	34
170	Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process. <i>Haemophilia</i> , 2004, 10, 232-242.	1.0	33
171	Standardization, Regulation, Quality Assurance and Emerging Technologies in Hemostasis: Issues, Controversies, Benefits, and Limitations. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 290-297.	1.5	33
172	Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 309-321.	1.4	33
173	Biological therapies for von Willebrand disease. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 551-564.	1.4	33
174	Diagnostics of Inherited Bleeding Disorders of Secondary Hemostasis: An Easy Guide for Routine Clinical Laboratories. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 471-477.	1.5	33
175	Critical pre-examination variables in the hemostasis laboratory and their quality indicators. <i>Clinical Biochemistry</i> , 2016, 49, 1315-1320.	0.8	33
176	Laboratory hemostasis: from biology to the bench. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1035-1045.	1.4	33
177	von Willebrand disease: laboratory aspects of diagnosis and treatment. <i>Haemophilia</i> , 2004, 10, 164-168.	1.0	32
178	Laboratory assessment and perioperative management of patients on antiplatelet therapy: From the bench to the bedside. <i>Clinica Chimica Acta</i> , 2009, 405, 8-16.	0.5	32
179	Technical Evaluation of the Novel Preanalytical Module on Instrumentation Laboratory ACL TOP: Advancing Automation in Hemostasis Testing. <i>Journal of the Association for Laboratory Automation</i> , 2013, 18, 382-390.	2.8	32
180	A Review of $\beta$ 2-Glycoprotein-I Antibody Testing Results From a Peer-Driven Multilaboratory Quality Assurance Program. <i>American Journal of Clinical Pathology</i> , 2007, 127, 441-448.	0.4	31

#	ARTICLE	IF	CITATIONS
181	Pharmacogenetics of vitamin K antagonists: useful or hype?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 503-15.	1.4	31
182	Novel and Emerging Therapies: Thrombus-Targeted Fibrinolysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 048-058.	1.5	31
183	Laboratory testing for the new oral anticoagulants: a review of current practice. <i>Pathology</i> , 2013, 45, 435-437.	0.3	31
184	Laboratory Testing for Von Willebrand Factor Multimers. <i>Methods in Molecular Biology</i> , 2017, 1646, 495-511.	0.4	31
185	Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 055-071.	1.5	31
186	Biomedical research platforms and their influence on article submissions and journal rankings: An update. <i>Biochemia Medica</i> , 0, , 7-14.	1.2	31
187	Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 447-461.	1.4	31
188	Potential indirect anti-inflammatory effects of IL-4. Stimulation of human monocytes, macrophages, and endothelial cells by IL-4 increases aminopeptidase-N activity (CD13; EC 3.4.11.2). <i>Journal of Immunology</i> , 1994, 153, 2718-28.	0.4	31
189	Laboratory Diagnosis of von Willebrand Disorder. <i>American Journal of Clinical Pathology</i> , 2003, 119, 882-893.	0.4	30
190	Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 362-365.	1.0	30
191	External Quality Assessment/Proficiency Testing and Internal Quality Control for the PFA-100 and PFA-200: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 239-253.	1.5	30
192	Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. <i>Expert Review of Hematology</i> , 2015, 8, 527-542.	1.0	30
193	Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 299-319.	0.7	29
194	The Journal Impact Factor: don't expect its demise any time soon. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1319-24.	1.4	29
195	Investigations from External Quality Assurance Programs Reveal a High Degree of Variation in the Laboratory Identification of Coagulation Factor Inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 794-805.	1.5	29
196	Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 587-590.	1.5	29
197	Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part I. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 257-259.	1.5	29
198	2011 Eberhard F. Mammen Award Announcements. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 431-439.	1.5	29

#	ARTICLE	IF	CITATIONS
199	Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. <i>Pathology</i> , 2017, 49, 639-643.	0.3	29
200	Air pollution and coagulation testing: A new source of biological variability?. <i>Thrombosis Research</i> , 2008, 123, 50-54.	0.8	28
201	A Consensus Approach to the Formulation of Guidelines for Laboratory Testing and Reporting of Antiphospholipid Antibody Assays. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 361-372.	1.5	28
202	Tirofiban and Activated Protein C Synergistically Inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from Allogeneic Islet Cells Exposure to Human Blood. <i>American Journal of Transplantation</i> , 2009, 9, 1533-1540.	2.6	28
203	Rethinking the diagnosis of von Willebrand disease. <i>Thrombosis Research</i> , 2011, 127, S17-S21.	0.8	28
204	Endothelial Cells and Normal Circulating Haemopoietic Cells Share a Number of Surface Antigens. <i>Thrombosis and Haemostasis</i> , 1989, 61, 217-224.	1.8	28
205	Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 7-17.	1.4	28
206	Laboratory Testing, Diagnosis, and Management of von Willebrand Disease: Current Practice in Australasia. <i>American Journal of Clinical Pathology</i> , 1999, 112, 712-719.	0.4	27
207	Preanalytical variables in coagulation testing. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 86-89.	0.5	27
208	Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 398-406.	0.7	27
209	Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2842-2844.	1.9	27
210	Laboratory testing in pharmacies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 943-953.	1.4	27
211	Laboratory testing for factor inhibitors. <i>Haemophilia</i> , 2014, 20, 94-98.	1.0	27
212	Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests. <i>American Journal of Hematology</i> , 2020, 95, 117-128.	2.0	27
213	A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 417-428.	1.9	27
214	CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. <i>Experimental Hematology</i> , 1993, 21, 1695-701.	0.2	27
215	CD13 (gp150 <sup>TM</sup> ; aminopeptidase-N): Co-expression on endothelial and haemopoietic cells with conservation of functional activity. <i>Immunology and Cell Biology</i> , 1991, 69, 253-260.	1.0	26
216	Diagnostic Issues in Thrombophilia: A Laboratory Scientist's View. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 11-16.	1.5	26

#	ARTICLE	IF	CITATIONS
217	Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 798-809.	1.5	26
218	Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 706-714.	0.5	26
219	Coagulation update: What's new in hemostasis testing?. <i>Thrombosis Research</i> , 2011, 127, S13-S16.	0.8	26
220	2012 Eberhard F. Mammen Award Announcements. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 425-432.	1.5	26
221	Coffee Intake and Cardiovascular Disease: Virtue Does Not Take Center Stage. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 164-177.	1.5	26
222	Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 269-274.	0.7	26
223	Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 411-414.	1.9	26
224	Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb). <i>Methods in Molecular Biology</i> , 2017, 1646, 453-460.	0.4	26
225	Laboratory testing for <scp>ADAMTS13</scp>: Utility for <scp>TTP</scp> diagnosis/exclusion and beyond. <i>American Journal of Hematology</i> , 2021, 96, 1049-1055.	2.0	26
226	Evaluating errors in the laboratory identification of von Willebrand disease using contemporary von Willebrand factor assays. <i>Pathology</i> , 2022, 54, 308-317.	0.3	26
227	Identification of von Willebrand Disease Type 2N (Normandy) in Australia. <i>American Journal of Clinical Pathology</i> , 2002, 118, 269-276.	0.4	25
228	An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. <i>Pathology</i> , 2005, 37, 234-238.	0.3	25
229	Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?. <i>Haematologica</i> , 2007, 92, 292-296.	1.7	25
230	Welcome to a Special Issue of <i>Seminars in Thrombosis and Hemostasis</i> – The Closing Issue for 2008. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 693-695.	1.5	25
231	Influence of Residual Platelet Count on Routine Coagulation, Factor VIII, and Factor IX Testing in Postfreeze-Thaw Samples. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 834-839.	1.5	25
232	A Review of the Value of D-dimer Testing for Prediction of Recurrent Venous Thromboembolism with Increasing Age. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 634-639.	1.5	25
233	von Willebrand disease and platelet disorders. <i>Haemophilia</i> , 2014, 20, 59-64.	1.0	25
234	Monitoring Therapy during Treatment of von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 338-354.	1.5	25

#	ARTICLE	IF	CITATIONS
235	Quality in coagulation and haemostasis testing. <i>Biochemia Medica</i> , 0, , 184-199.	1.2	25
236	How Useful is the Monitoring of (Low Molecular Weight) Heparin Therapy by Anti-Xa Assay? A Laboratory Perspective. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2005, 11, 157-162.	1.2	25
237	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1999-2001.	1.9	24
238	Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 755-7.	1.4	24
239	Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders. <i>Haemophilia</i> , 2012, 18, 66-72.	1.0	24
240	Laboratory hemostasis: milestones in <i>Clinical Chemistry and Laboratory Medicine</i> . <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 91-97.	1.4	24
241	2013 Eberhard F. Mammen Award Announcements. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 567-574.	1.5	24
242	Technological Advances in the Hemostasis Laboratory. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 178-185.	1.5	24
243	Influence of posture on routine hemostasis testing. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 716-719.	0.5	24
244	Harmonizing the International Normalized Ratio (INR). <i>American Journal of Clinical Pathology</i> , 2016, 145, 191-202.	0.4	24
245	Translational aspects of developmental hemostasis: infants and children are not miniature adults and even adults may be different. <i>Annals of Translational Medicine</i> , 2017, 5, 212-212.	0.7	24
246	Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. <i>American Journal of Clinical Pathology</i> , 2005, 124, 910-7.	0.4	24
247	Myeloid progenitor surface antigen identified by monoclonal antibody. <i>British Journal of Haematology</i> , 1985, 61, 11-20.	1.2	23
248	Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 729-737.	0.5	23
249	Laboratory Monitoring of Therapy in von Willebrand Disease: Efficacy of the PFA-100 and von Willebrand Factor:Collagen-Binding Activity as Coupled Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 566-576.	1.5	23
250	Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 475-483.	0.5	23
251	The Spectrum of Coagulation Abnormalities in Thyroid Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 007-010.	1.5	23
252	Dangers in the Practice of Defensive Medicine in Hemostasis Testing for Investigation of Bleeding or Thrombosis: Part I – Routine Coagulation Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 812-824.	1.5	23

#	ARTICLE	IF	CITATIONS
253	The Platelet Function Analyser (<sc>PFA</sc>)â€100 and von Willebrand disease: a story well over 16Âyears in the making. Haemophilia, 2015, 21, 642-645.	1.0	23
254	Explaining and reducing the variation in inter-laboratory reported values for International Normalised Ratio. Thrombosis Research, 2017, 150, 22-29.	0.8	23
255	Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study. Thrombosis Research, 2018, 166, 96-105.	0.8	23
256	Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand's Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thrombosis and Haemostasis, 2000, 83, 127-35.	1.8	23
257	Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor. American Journal of Hematology, 2001, 66, 53-56.	2.0	22
258	Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1079-1090.	1.4	22
259	A clinical audit of congenital thrombophilia investigation in tertiary practice. Pathology, 2011, 43, 266-272.	0.3	22
260	von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder. Seminars in Thrombosis and Hemostasis, 2011, 37, 425-426.	1.5	22
261	Influence of mechanical trauma of blood and hemolysis on PFA-100 testing. Blood Coagulation and Fibrinolysis, 2012, 23, 82-86.	0.5	22
262	Platelet function testing in pediatric patients. Expert Review of Hematology, 2017, 10, 281-288.	1.0	22
263	Managing the patient identification crisis in healthcare and laboratory medicine. Clinical Biochemistry, 2017, 50, 562-567.	0.8	22
264	Danger of false negative (exclusion) or false positive (diagnosis) for â€congenital thrombophiliaâ€™ in the age of anticoagulants. Clinical Chemistry and Laboratory Medicine, 2019, 57, 873-882.	1.4	22
265	Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2020, 46, 859-862.	1.5	22
266	Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies. Haemophilia, 2020, 26, 503-512.	1.0	22
267	Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 278-284.	1.0	22
268	A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia. Pathology, 2021, 53, 247-256.	0.3	22
269	Immunophenotype of clonogenic cells in myeloid leukaemia. Leukemia Research, 1988, 12, 51-59.	0.4	21
270	Laboratory Assessment of von Willebrand Factor: Altered Interpretation of Laboratory Data, and Altered Diagnosis of von Willebrand's Disease. Clinical and Applied Thrombosis/Hemostasis, 1997, 3, 110-118.	0.7	21



#	ARTICLE	IF	CITATIONS
271	A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. <i>Pathology</i> , 2002, 34, 348-355.	0.3	21
272	2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease. <i>British Journal of Haematology</i> , 2006, 135, 141-142.	1.2	21
273	A Tribute to Eberhard F. Mammen, M.D. (1930â€“2008). <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 703-707.	1.5	21
274	Quality issues in laboratory haemostasis. <i>Haemophilia</i> , 2010, 16, 93-99.	1.0	21
275	Inherited disorders of blood coagulation. <i>Annals of Medicine</i> , 2012, 44, 405-418.	1.5	21
276	Pearls and pitfalls in factor inhibitor assays. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 52-60.	0.7	21
277	The Changing Face of Hemostasis Testing in Modern Laboratories: Consolidation, Automation, and Beyond. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 294-299.	1.5	21
278	Evaluation of a new commercial von Willebrand factor multimer assay. <i>Haemophilia</i> , 2017, 23, e373-e377.	1.0	21
279	Dark chocolate modulates platelet function with a mechanism mediated by flavan-3-ol metabolites. <i>Medicine (United States)</i> , 2018, 97, e13432.	0.4	21
280	Anticoagulation at the extremes of body weight: choices and dosing. <i>Expert Review of Hematology</i> , 2018, 11, 817-828.	1.0	21
281	The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA). <i>American Journal of Hematology</i> , 2019, 94, 1290-1296.	2.0	21
282	Diagnosis and management of heparinâ€“induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand<sc>HIT</sc>Writing Group. <i>Medical Journal of Australia</i> , 2019, 210, 509-516.	0.8	21
283	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)â€“Part I. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 757-762.	1.5	21
284	Mean Platelet Volume Predicts Severe COVID-19 Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 456-459.	1.5	21
285	Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data. <i>Blood Advances</i> , 2022, 6, 416-419.	2.5	21
286	Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12676.	1.0	21
287	The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. <i>Clinica Chimica Acta</i> , 1993, 220, 81-90.	0.5	20
288	Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1. <i>British Journal of Haematology</i> , 1995, 89, 582-588.	1.2	20

#	ARTICLE	IF	CITATIONS
289	Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results. <i>Haemophilia</i> , 1996, 2, 218-223.	1.0	20
290	Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2085-2088.	1.9	20
291	Dark chocolate: consumption for pleasure or therapy?. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 482-488.	1.0	20
292	External Quality Assessment of Factor VIII Inhibitor Assays. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 320-326.	1.5	20
293	The futility of thrombophilia testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 499-503.	1.4	20
294	Newer Hemostatic Agents. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 802-808.	1.5	20
295	Critical laboratory values in hemostasis: toward consensus. <i>Annals of Medicine</i> , 2017, 49, 455-461.	1.5	20
296	Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease. <i>Haemophilia</i> , 2018, 24, 198-210.	1.0	20
297	Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene Mutation (G20210A). <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 730-742.	1.5	20
298	Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making. <i>Thrombosis Research</i> , 2020, 188, 17-24.	0.8	20
299	The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 547-558.	0.7	20
300	Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: A comparison of acute myeloid leukaemia and normal bone marrow cells. <i>American Journal of Hematology</i> , 1986, 23, 43-50.	2.0	19
301	Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease. <i>British Journal of Haematology</i> , 1999, 105, 538-541.	1.2	19
302	One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 1-3.	0.5	19
303	Hot Topics IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 001-004.	1.5	19
304	Interference from heterophilic antibodies in D-dimer assessment. A case report. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 277-279.	0.5	19
305	International Normalized Ratio Monitoring of Vitamin K Antagonist Therapy: Comparative Performance of Point-of-Care and Laboratory-Derived Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 279-286.	1.5	19
306	Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB). <i>Methods in Molecular Biology</i> , 2017, 1646, 417-433.	0.4	19

#	ARTICLE	IF	CITATIONS
307	Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo). <i>Methods in Molecular Biology</i> , 2017, 1646, 435-451.	0.4	19
308	Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. <i>Internal Medicine Journal</i> , 2019, 49, 59-65.	0.5	19
309	Navigating the Myriad of von Willebrand Factor Assays. <i>Hamostaseologie</i> , 2020, 40, 431-442.	0.9	19
310	Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 451-455.	1.5	19
311	Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? A Focus on Clinical Considerations and Recommendations. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 755-768.	0.7	19
312	Laboratory Identification of Familial Thrombophilia: Do the Pitfalls Exceed the Benefits? A Reassessment of ABO-Blood Group, Gender, Age, and other Laboratory Parameters on the Potential Influence on a Diagnosis of Protein C, Protein S, and Antithromb. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2005, 11, 174-184.	1.2	19
313	Advances in hematology. Etiology and diagnosis of acquired von Willebrand syndrome. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 20-4.	0.3	19
314	Diagnosis and Management of von Willebrand Disease in Australia. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 542-554.	1.5	18
315	External Quality Assurance for Heparin Monitoring. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 632-639.	1.5	18
316	Sample collection and platelet function testing. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 666-669.	0.5	18
317	Problems and Solutions in Laboratory Testing for Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 135-135.	1.5	18
318	Diagnostics in Venous Thromboembolism: From Origin to Future Prospects. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 374-381.	1.5	18
319	Sodium citrate blood contamination by K <sub>2</sub> ethylenediaminetetraacetic acid (<sc>EDTA</sc>): impact on routine coagulation testing. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 403-409.	0.7	18
320	Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?. <i>American Journal of Hematology</i> , 2018, 93, 308-314.	2.0	18
321	How to Generate a More Accurate Laboratory-Based International Normalized Ratio: Solutions to Obtaining or Verifying the Mean Normal Prothrombin Time and International Sensitivity Index. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 010-021.	1.5	18
322	Semi-automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 762-771.	0.7	18
323	Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 008-014.	1.5	18
324	Rare Bleeding Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 345-347.	1.5	17

#	ARTICLE	IF	CITATIONS
325	D-Dimer Measurement and Laboratory Feedback. <i>Journal of Emergency Medicine</i> , 2009, 37, 82-83.	0.3	17
326	Recombinant Platelet Factor 4: A Therapeutic, Anti-Neoplastic Chimera?. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 558-569.	1.5	17
327	Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 170-176.	0.7	17
328	2014 Eberhard F. Mammen Award Announcements: Part 1 – Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 407-412.	1.5	17
329	Optimizing the Verification of Mean Normal Prothrombin Time (MNPT) and International Sensitivity Index (ISI) for Accurate Conversion of Prothrombin Time (PT) to International Normalized Ratio (INR). <i>Methods in Molecular Biology</i> , 2017, 1646, 59-74.	0.4	17
330	Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 228-246.	1.5	17
331	Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study). <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 103-112.	1.0	17
332	Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 975-988.	1.9	17
333	A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 3494-3506.	2.5	17
334	D-dimer: old dogmas, new (COVID-19) tricks. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 841-850.	1.4	17
335	The MDA-180 coagulation analyser: a laboratory evaluation. <i>Pathology</i> , 1997, 29, 176-183.	0.3	16
336	Template bleeding time and PFA-100R have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients - a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2280-2282.	1.9	16
337	Laboratory medicine and natural disasters: are we ready for the challenge?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 573-575.	1.4	16
338	Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 292-295.	0.5	16
339	Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care. <i>Diagnosis</i> , 2014, 1, 311-312.	1.2	16
340	Why Do Patients Bleed?. <i>The Surgery Journal</i> , 2016, 02, e29-e43.	0.3	16
341	Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing. <i>Methods in Molecular Biology</i> , 2017, 1646, 391-402.	0.4	16
342	Oral anticoagulants around the world: an updated state-of-the art analysis. <i>Annals of Blood</i> , 0, 3, 49-49.	0.4	16

#	ARTICLE	IF	CITATIONS
343	An update on quality control for the PFA-100/PFA-200. <i>Platelets</i> , 2018, 29, 622-627.	1.1	16
344	Analytical Assessment of the New Roche Cobas t 711 Fully Automated Coagulation Analyzer. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 308-314.	1.5	16
345	International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 398-409.	1.5	16
346	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 333-337.	1.5	16
347	Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty a novel approach to standardisation. <i>Pathology</i> , 2008, 40, 277-287.	0.3	15
348	Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 654-664.	1.5	15
349	The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?. <i>Autoimmunity Highlights</i> , 2010, 1, 5-14.	3.9	15
350	Influenza and Cardiovascular Disease: Does Swine-Origin, 2009 H1N1 Flu Virus Represent a Risk Factor, an Acute Trigger, or Both?. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 049-058.	1.5	15
351	Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag). <i>Methods in Molecular Biology</i> , 2017, 1646, 403-416.	0.4	15
352	Laboratory monitoring of direct oral anticoagulants (DOACs)â€”The perfect storm?. <i>Annals of Translational Medicine</i> , 2017, 5, 6-6.	0.7	15
353	Development and implementation of an expert rule set for automated reflex testing and validation of routine coagulation tests in a large pathology network. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 642-649.	0.7	15
354	Towards personalised therapy for von Willebrand disease: a future role for recombinant products. <i>Blood Transfusion</i> , 2016, 14, 262-76.	0.3	15
355	Haemolysis index for the screening of intravascular haemolysis: a novel diagnostic opportunity?. <i>Blood Transfusion</i> , 2018, 16, 433-437.	0.3	15
356	Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS. <i>Antibodies</i> , 2022, 11, 7.	1.2	15
357	Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. <i>Haemophilia</i> , 2010, 16, 662-670.	1.0	14
358	Antisense therapy in the treatment of hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2011, 22, 541-546.	1.0	14
359	Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 613-621.	1.5	14
360	Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 203-207.	0.5	14

#	ARTICLE	IF	CITATIONS
361	A novel flow cytometry single tube bead assay for quantitation of von Willebrand factor antigen and collagen-binding. <i>Thrombosis and Haemostasis</i> , 2012, 108, 999-1005.	1.8	14
362	Article downloads and citations: Is there any relationship?. <i>Clinica Chimica Acta</i> , 2013, 415, 195.	0.5	14
363	2014 Eberhard F. Mammen Award Announcements: Part IIâ€”Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 718-723.	1.5	14
364	Next Generation Antithrombotic Therapy: Focus on Antisense Therapy against Coagulation Factor XI. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 255-262.	1.5	14
365	Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell Transplantation. <i>Transplantation Direct</i> , 2016, 2, e77.	0.8	14
366	The Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 609-613.	1.5	14
367	Gender related issues in thrombosis and hemostasis. <i>Expert Review of Hematology</i> , 2017, 10, 941-949.	1.0	14
368	Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD). <i>Methods in Molecular Biology</i> , 2017, 1646, 461-472.	0.4	14
369	Time dependent reduction in platelet aggregation using the multiplate analyser and hirudin blood due to platelet clumping. <i>Platelets</i> , 2018, 29, 305-308.	1.1	14
370	On the complexity of hemostasis and the need for harmonization of test practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1568-1574.	1.4	14
371	Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 784-792.	1.5	14
372	Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 157-163.	1.5	14
373	Platelet Transfusion Thresholds: How Low Can We Go in Respect to Platelet Counting?. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 238-244.	1.5	14
374	Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. <i>Pathology</i> , 1985, 17, 392-399.	0.3	14
375	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)â€”Part III. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 003-007.	1.5	14
376	Characterization of a p43 human thymocyte antigen. <i>Disease Markers</i> , 1986, 4, 261-70.	0.6	14
377	Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. <i>British Journal of Biomedical Science</i> , 1999, 56, 23-33.	1.2	14
378	Cell-Free DNA, Neutrophil extracellular traps (NETs), and Endothelial Injury in Coronavirus Disease 2019â€”(COVID-19â€”) Associated Acute Kidney Injury. <i>Mediators of Inflammation</i> , 2022, 2022, 1-8.	1.4	14

#	ARTICLE	IF	CITATIONS
379	A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays. <i>Haemophilia</i> , 2002, 8, 828-831.	1.0	13
380	Activated protein C resistance: The influence of ABO-blood group, gender and age. <i>Thrombosis Research</i> , 2006, 117, 665-670.	0.8	13
381	Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part II. Seminars in Thrombosis and Hemostasis, 2009, 35, 591-595.	1.5	13
382	Diagnostic Evaluation of Platelet Disorders: The Past, the Present, and the Future. Seminars in Thrombosis and Hemostasis, 2009, 35, 127-130.	1.5	13
383	Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. <i>Pathology</i> , 2009, 41, 666-675.	0.3	13
384	Holiday Thrombosis. Seminars in Thrombosis and Hemostasis, 2011, 37, 869-874.	1.5	13
385	Towards harmonization of external quality assessment/proficiency testing in hemostasis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 57, 115-126.	1.4	13
386	To Maintain or Cease Non-Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations. Seminars in Thrombosis and Hemostasis, 2019, 45, 171-179.	1.5	13
387	Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. <i>Haemophilia</i> , 2020, 26, 354-362.	1.0	13
388	How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. <i>Haemophilia</i> , 2021, 27, 137-148.	1.0	13
389	Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. <i>American Journal of Clinical Pathology</i> , 2004, 122, 686-92.	0.4	13
390	Futility of testing for factor V Leiden. <i>Blood Transfusion</i> , 2012, 10, 260-3.	0.3	13
391	Filtered plasma as a potential cause of clinical misdiagnosis: inappropriate testing in a haematology laboratory. <i>British Journal of Biomedical Science</i> , 1995, 52, 243-8.	1.2	13
392	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. <i>Thrombosis and Haemostasis</i> , 2007, 97, 922-30.	1.8	13
393	Learning from Peer Assessment: The Role of the External Quality Assurance Multilaboratory Thrombophilia Test Process. Seminars in Thrombosis and Hemostasis, 2005, 31, 85-89.	1.5	12
394	Emerging Technologies and Quality Assurance in Hemostasis: A Review of Findings from the Royal College of Pathologists of Australasia Quality Assurance Program. Seminars in Thrombosis and Hemostasis, 2007, 33, 235-242.	1.5	12
395	The genetic basis of human athletic performance. Why are psychological components so often overlooked?. <i>Journal of Physiology</i> , 2008, 586, 3017-3017.	1.3	12
396	Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. <i>Internal Medicine Journal</i> , 2012, 42, 427-434.	0.5	12

#	ARTICLE	IF	CITATIONS
397	Lupus anticoagulant testing “ sometimes mixing is required. Blood Coagulation and Fibrinolysis, 2013, 24, 673-676.	0.5	12
398	A Short History of Thrombosis and Hemostasis: Part I (40th Year Celebratory Issue). Seminars in Thrombosis and Hemostasis, 2014, 40, 521-525.	1.5	12
399	2015 Eberhard F. Mammen Award Announcements: Part “Most Popular Articles. Seminars in Thrombosis and Hemostasis, 2015, 41, 673-679.	1.5	12
400	Allergy and Venous Thromboembolism: A Casual or Causative Association. Seminars in Thrombosis and Hemostasis, 2016, 42, 063-068.	1.5	12
401	Potential misdiagnosis of von Willebrand disease and haemophilia caused by ineffective mixing of thawed plasma. Haemophilia, 2017, 23, e436-e443.	1.0	12
402	Recent initiatives in harmonization of hemostasis practice. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1608-1619.	1.4	12
403	e-thrombosis: epidemiology, physiopathology and rationale for preventing computer-related thrombosis. Annals of Translational Medicine, 2018, 6, 344-344.	0.7	12
404	Rare forms of von Willebrand disease. Annals of Translational Medicine, 2018, 6, 345-345.	0.7	12
405	Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1784-1789.	1.4	12
406	Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. Expert Review of Hematology, 2021, 14, 335-346.	1.0	12
407	The missing link between genotype, phenotype and clinics. Biochimica Medica, 0, , 137-145.	1.2	12
408	Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives. Blood Transfusion, 2017, 15, 491-494.	0.3	12
409	Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia. Pathology, 2022, 54, 254-261.	0.3	12
410	D-dimers “Normal” Levels versus Elevated Levels Due to a Range of Conditions, Including D-dimeritis, Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Seminars in Thrombosis and Hemostasis, 2022, 48, 672-679.	1.5	12
411	Time to Think Outside the Box? Proposals for a New Approach to Future Pharmacokinetic Studies of von Willebrand Factor Concentrates in People with von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2007, 33, 745-758.	1.5	11
412	Cardiac biomarkers in pulmonary embolism. Thrombosis and Haemostasis, 2008, 99, 1134-1136.	1.8	11
413	Proficiency testing/external quality assurance for the PFA-100®. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1393-401.	1.4	11
414	Evaluating laboratory approaches to the identification of lupus anticoagulants: A diagnostic challenge from the RCPA Haematology QAP. Pathology, 2012, 44, 240-247.	0.3	11



#	ARTICLE	IF	CITATIONS
415	Trials and tribulations in lupus anticoagulant testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 253-256.	1.4	11
416	Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 767-774.	1.4	11
417	A Short History of Thrombosis and Hemostasis: Part II (40th Year Celebratory Issue). <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 826-830.	1.5	11
418	Recent advances in laboratory-aided diagnosis of von Willebrand disease. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 975-995.	0.5	11
419	Anticoagulant Therapy: Present and Future. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 109-112.	1.5	11
420	Mixing of thawed coagulation samples prior to testing: Is any technique better than another?. <i>Clinical Biochemistry</i> , 2016, 49, 1399-1401.	0.8	11
421	Laboratory Testing for Activated Protein C Resistance (APCR). <i>Methods in Molecular Biology</i> , 2017, 1646, 137-143.	0.4	11
422	Understanding the "philosophy" of laboratory hemostasis. <i>Diagnosis</i> , 2019, 6, 223-226.	1.2	11
423	Verification of the ACL Top 50 Family (350, 550, and 750) for Harmonization of Routine Coagulation Assays in a Large Network of 60 Laboratories. <i>American Journal of Clinical Pathology</i> , 2021, 156, 661-678.	0.4	11
424	Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2857-2861.	1.9	11
425	Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1322-1331.	1.4	11
426	Laboratory Diagnosis of von Willebrand Disorder: Use of Multiple Functional Assays Reduces Diagnostic Error Rates. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2005, 11, 91-97.	1.2	11
427	Standardization of monoclonal antibodies for use in autologous bone marrow transplantation for common acute lymphoblastic leukemia. <i>Pathology</i> , 1986, 18, 197-205.	0.3	11
428	The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, , .	1.5	11
429	Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 711-731.	1.5	11
430	Potential benefits of improved protein intake in older people. <i>Nutrition and Dietetics</i> , 2008, 65, 151-156.	0.9	10
431	Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 175-180.	1.5	10
432	Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1965-73.	1.4	10

#	ARTICLE	IF	CITATIONS
433	Massive Posttraumatic Bleeding: Epidemiology, Causes, Clinical Features, and Therapeutic Management. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 083-093.	1.5	10
434	Standardization and Harmonization of Antiphospholipid Antibody Assays. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 161-162.	1.5	10
435	2015 Eberhard F. Mammen Award Announcements: Part IIâ€”Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 809-815.	1.5	10
436	Toward improved diagnosis of HIT. <i>Blood</i> , 2015, 126, 563-564.	0.6	10
437	2016 Eberhard F. Mammen Award Announcements: Part I â€” Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 325-330.	1.5	10
438	Laboratory Testing Protocols for Heparin-Induced Thrombocytopenia (HIT) Testing. <i>Methods in Molecular Biology</i> , 2017, 1646, 227-243.	0.4	10
439	The increasing maturity of the von Willebrand factor collagen binding in von Willebrand disease diagnosis. <i>Haemophilia</i> , 2018, 24, 20-23.	1.0	10
440	Car Travel-Related Thrombosis: Fact or Fiction?. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 327-333.	1.5	10
441	Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e413-e415.	1.4	10
442	Platelet Function Testing: Auditing Local Practice and Broader Implications. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2010, 23, 21-31.	0.1	10
443	Improving the Inter-Laboratory Harmonization of the International Normalized Ratio (INR): Utilizing the Concept of Transference to Estimate and/or Validate International Sensitivity Index (ISI) and Mean Normal Prothrombin Time (MNPT) Values and/or to Eliminate Measurement Bias. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2012, 25, 13-25.	0.1	10
444	The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	1.0	10
445	What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 027-033.	1.5	10
446	Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33). <i>Disease Markers</i> , 1987, 5, 215-25.	0.6	10
447	TRANSPLANTATION OF MONOCLONAL ANTIBODYâ€”PURGED AUTOLOGOUS BONE MARROW FOR TREATMENT OF POOR RISK COMMON ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Australian and New Zealand Journal of Medicine</i> , 1987, 17, 283-289.	0.5	9
448	Medical research in New South Wales 1993â€”1996 assessed by Medline publication capture. <i>Medical Journal of Australia</i> , 1998, 169, 617-622.	0.8	9
449	Laboratory Diagnosis of von Willebrand Disorder: Current Practice in the Southern Hemisphere. <i>American Journal of Clinical Pathology</i> , 2003, 119, 882-893.	0.4	9
450	Evaluation of primary haemostasis in people with neurofibromatosis type 1. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 341-345.	0.2	9

#	ARTICLE	IF	CITATIONS
451	Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 441-448.	0.5	9
452	2B or not 2B? Differential identification of type 2B, versus pseudo-, von Willebrand disease ? response to Whalley and Perry. <i>British Journal of Haematology</i> , 2007, 136, 345-346.	1.2	9
453	Antiphospholipid Antibodies and the Antiphospholipid Syndrome I: Pathogenesis, Clinical Features, Diagnosis, and Management. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 213-218.	1.5	9
454	Antiphospholipid Antibodies and the Antiphospholipid Syndrome II: Limitations, Standardization, and Clinical Utility of Laboratory Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 309-312.	1.5	9
455	Discard Tubes Are Sometimes Necessary When Drawing Samples for Hemostasis The Authors' Reply. <i>American Journal of Clinical Pathology</i> , 2010, 134, 851-852.	0.4	9
456	Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008-2009. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 685-692.	1.5	9
457	External quality assurance for the PFA-100®. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 878-880.	1.9	9
458	Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 360-366.	1.0	9
459	2B or not 2B? Masquerading as von Willebrand disease?. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 317-319.	1.9	9
460	Post-analytical Issues in Hemostasis and Thrombosis Testing. <i>Methods in Molecular Biology</i> , 2017, 1646, 545-559.	0.4	9
461	Hemostasis practice: state-of-the-art. <i>Journal of Laboratory and Precision Medicine</i> , 0, 3, 67-67.	1.1	9
462	Anticoagulation therapy in Australia. <i>Annals of Blood</i> , 0, 3, 48-48.	0.4	9
463	Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 339-345.	0.5	9
464	Variability in D-dimer reporting revisited. <i>Pathology</i> , 2021, 53, 538-540.	0.3	9
465	A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1709-1718.	1.4	9
466	The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 115.	0.8	9
467	Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1276-82.	1.8	9
468	The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer. <i>Healthcare (Switzerland)</i> , 2022, 10, 557.	1.0	9

#	ARTICLE	IF	CITATIONS
469	A multi-laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 654-665.	0.7	9
470	Harmonizing platelet function analyzer testing and reporting in a large laboratory network. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 934-944.	0.7	9
471	Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations. , 2000, 63, 197-199.		8
472	Sulfatide-Binding Assay for von Willebrand Factor. <i>Thrombosis Research</i> , 2000, 98, 213-219.	0.8	8
473	More on 'universal' versus 'selected' screening for thrombophilia: the hidden costs of false-positive diagnosis. <i>British Journal of Haematology</i> , 2006, 134, 239-240.	1.2	8
474	Differential identification of PT-VWD from type 2B VWD and <i>GP1BA</i> nomenclature issues response to Othman. <i>British Journal of Haematology</i> , 2008, 142, 314-315.	1.2	8
475	Recombinants in Thrombosis and Hemostasis: From Basic Research to Clinical Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 471-476.	1.5	8
476	Platelets, Inflammation and Cardiovascular Diseases. New Concepts and Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 129-130.	1.5	8
477	Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 220-222.	1.9	8
478	Venous Thromboembolism in Chronic Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 066-076.	1.5	8
479	Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations. Part V.. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 859-862.	1.5	8
480	Andexanet: Effectively Reversing Anticoagulation. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 413-414.	4.0	8
481	Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A. <i>Advances in Clinical Chemistry</i> , 2019, 88, 151-167.	1.8	8
482	Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 952-957.	1.0	8
483	2020 Eberhard F. Mammen Award Announcements: Part 1 "Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 383-392.	1.5	8
484	Oral anticoagulation therapy: an update on usage, costs and associated risks. <i>Pathology</i> , 2020, 52, 736-741.	0.3	8
485	Statins and other drugs: Facing COVID-19 as a vascular disease. <i>Pharmacological Research</i> , 2020, 159, 105033.	3.1	8
486	The changing face of activated protein C resistance testing—a 10-year retrospective. <i>Annals of Blood</i> , 0, 5, 6-6.	0.4	8

#	ARTICLE	IF	CITATIONS
487	A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. <i>Thrombosis and Haemostasis</i> , 2002, 87, 466-76.	1.8	8
488	2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12635.	1.0	8
489	Heparin: The Journey from Parenteral Agent to Nasal Delivery. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 949-954.	1.5	8
490	Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A. , 1999, 62, 199-200.		7
491	High Rate of Deficiency in the Amino Acids Tryptophan and Histidine in People with Wounds. <i>Advances in Skin and Wound Care</i> , 2009, 22, 79-82.	0.5	7
492	Prevalence of hypokalaemia: the experience of a large academic hospital. <i>Internal Medicine Journal</i> , 2010, 40, 315-316.	0.5	7
493	2009 Eberhard F. Mammen Young Investigator Award Winners. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 469-470.	1.5	7
494	A robust method for testing urinary iodine using a microtitre robotic system. <i>Journal of Trace Elements in Medicine and Biology</i> , 2011, 25, 213-217.	1.5	7
495	Iodine Deficiency: Current Aspects and Future Prospects. <i>Laboratory Medicine</i> , 2011, 42, 744-746.	0.8	7
496	Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 367-373.	1.0	7
497	Response to "Comment on E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism" <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 519-520.	1.5	7
498	Laboratory monitoring of warfarin in the era of direct oral anticoagulants. <i>Lancet Haematology</i> , the, 2015, 2, e223-e224.	2.2	7
499	Serum Concentration of Growth Differentiation Factor-15 Is Independently Associated with Global Platelet Function and Higher Fibrinogen Values in Adult Healthy Subjects. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 621-628.	1.5	7
500	2017 Eberhard F. Mammen Award Announcements: Part II "Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 357-363.	1.5	7
501	2018 Eberhard F. Mammen Award Announcements: Part II "Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 185-192.	1.5	7
502	Commentary: Controversies in Thrombosis and Hemostasis Part I "Hematomatidrosis: "Blood, Sweat and Fears" or A "Pigment of Fertile Imaginations"? <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 296-297.	1.5	7
503	Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives. <i>European Journal of Internal Medicine</i> , 2020, 76, 8-13.	1.0	7
504	2020 Eberhard F. Mammen Award Announcements: Part II "Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 229-237.	1.5	7

#	ARTICLE	IF	CITATIONS
505	Mean platelet volume in arterial and venous thrombotic disorders. <i>Journal of Laboratory Medicine</i> , 2020, 44, 305-312.	1.1	7
506	A survey of heparin monitoring in australasia. <i>Pathology</i> , 1996, 28, 343-347.	0.3	6
507	The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1434-1435.	1.9	6
508	Aspirin "responsiveness"™, "nonresponsiveness"™ or "resistance"™: a putative role for von Willebrand factor?. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 823-824.	0.5	6
509	Proteomic analysis of venous thromboembolism. <i>Expert Review of Proteomics</i> , 2010, 7, 275-282.	1.3	6
510	von Willebrand Factor Assay Proficiency Testing Continued. <i>American Journal of Clinical Pathology</i> , 2011, 136, 657-659.	0.4	6
511	The Antiphospholipid Syndrome: Diagnosis, Pathogenesis, Laboratory Testing, and Management. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 299-304.	1.5	6
512	Reflections on the next generation of hemostasis instrumentation. A glimpse into the future?. <i>Laboratoriums Medizin</i> , 2016, 40, 1-7.	0.1	6
513	Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data. <i>Drugs in Context</i> , 2016, 5, 1-10.	1.0	6
514	Editorial Compilation I. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 005-008.	1.5	6
515	Lack of grading agreement among international hemostasis external quality assessment programs. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 111-119.	0.5	6
516	von Willebrand Disease. , 2018, , 57-102.		6
517	Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 747-755.	1.5	6
518	A 2018 Update on the Editorial and Publication Policy of <i>Seminars in Thrombosis and Hemostasis</i> . <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 307-311.	1.5	6
519	Coagulation studies: achieving the right mix in a large laboratory network. <i>Pathology</i> , 2019, 51, 718-722.	0.3	6
520	Rethinking internal quality control and external quality assessment for laboratory diagnostics of von Willebrand disease. <i>Annals of Blood</i> , 0, 4, 4-4.	0.4	6
521	D-dimer measurement in COVID-19: Silver bullet or clinical distraction?. <i>Thrombosis Research</i> , 2020, 196, 635-637.	0.8	6
522	2021 Eberhard F. Mammen Award Announcements: Part I "Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 467-476.	1.5	6

#	ARTICLE	IF	CITATIONS
523	Impact of experimental hypercalcemia on routine haemostasis testing. PLoS ONE, 2017, 12, e0175094.	1.1	6
524	Emerging treatments for hemophilia: patients and their treaters spoiled for choice, but laboratories face a difficult path?. Annals of Translational Medicine, 2017, 5, 101-101.	0.7	6
525	Tranexamic acid to prevent post-partum haemorrhage. Blood Transfusion, 2018, 16, 321-323.	0.3	6
526	2022 Eberhard F. Mammen Award Announcements: Part 1 "Most Popular Articles. Seminars in Thrombosis and Hemostasis, 2022, 48, 502-513.	1.5	6
527	A Review of Autoimmune Acquired von Willebrand Factor Deficiency in Japan. Seminars in Thrombosis and Hemostasis, 2022, 48, 911-925.	1.5	6
528	Further studies on the heterogeneity of antigens recognised by CD41 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns. Immunology and Cell Biology, 1987, 65, 517-527.	1.0	5
529	Aminopeptidase-N (CD13; gp 150): Contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia. Leukemia Research, 1995, 19, 659-666.	0.4	5
530	2B or not 2B? What is the role of VWF in platelet-matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions. Journal of Thrombosis and Haemostasis, 2006, 4, 892-894.	1.9	5
531	Hot Topics I: A Potpourri of Current Issues and Controversies in Thrombosis and Hemostasis. Seminars in Thrombosis and Hemostasis, 2007, 33, 723-726.	1.5	5
532	Detection of duplicates and redundancies. A major responsibility of peer-reviewers?. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1796-7.	1.4	5
533	Laboratory Diagnostics in Thrombosis and Hemostasis: The Past, the Present, and the Future. Seminars in Thrombosis and Hemostasis, 2008, 34, 579-583.	1.5	5
534	Laboratory Diagnostics and Therapy in Thrombosis and Hemostasis: From Bedside to Bench to Bedside. Seminars in Thrombosis and Hemostasis, 2009, 35, 003-008.	1.5	5
535	Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease. Thrombosis Research, 2011, 127, 2-3.	0.8	5
536	Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. Thrombosis Research, 2011, 127, 161-166.	0.8	5
537	Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country?. Pathology, 2011, 43, 397-402.	0.3	5
538	More on preanalytical variables affecting platelet function testing using light transmittance aggregometry. Clinical Chemistry and Laboratory Medicine, 2011, 49, 737-9.	1.4	5
539	Hot Topics III. Seminars in Thrombosis and Hemostasis, 2012, 38, 01-04.	1.5	5
540	Quality in Hemostasis and Thrombosis "Part I. Seminars in Thrombosis and Hemostasis, 2012, 38, 549-552.	1.5	5

#	ARTICLE	IF	CITATIONS
541	Distinguishing types 1 and 2M von Willebrand disease. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 102-105.	0.7	5
542	Diagnosis of type 1 vs. 2A and 2M von Willebrand disease. <i>Haemophilia</i> , 2012, 18, e9-11.	1.0	5
543	Still more discussion on the journal impact factor. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, e283-4.	1.4	5
544	Evaluating the interaction of von Willebrand factor and ADAMTS13 - and perhaps also beyond ADAMTS13. <i>Thrombosis Research</i> , 2014, 134, 1167-1168.	0.8	5
545	Comparative sensitivity of commercially available aPTT reagents to mulga snake ( <i>Pseudechis australis</i> ) venom. <i>Pathology</i> , 2014, 46, 444-449.	0.3	5
546	The effect of hyperglycaemia on haemostasis testing – a volunteer study. <i>Anaesthesia</i> , 2015, 70, 549-554.	1.8	5
547	Novel (Oral) Anticoagulant Challenges in Surgery. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 706-715.	1.5	5
548	2016 Eberhard F. Mammen Award Announcements: Part II – Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 235-241.	1.5	5
549	Reference ranges in hemostasis testing: necessary but imperfect. <i>Journal of Laboratory and Precision Medicine</i> , 0, 2, 18-18.	1.1	5
550	Exploring the iceberg of inappropriateness in hemostasis testing. <i>Diagnosis</i> , 2017, 4, 1-2.	1.2	5
551	2017 Eberhard F. Mammen Award Announcements: Part II – Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 081-088.	1.5	5
552	Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease. <i>Haemophilia</i> , 2018, 24, 849-861.	1.0	5
553	Statins for Preventing Venous Thrombosis: For or Against?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 834-836.	1.5	5
554	Novel approaches to quality control and external quality assessment for platelet function testing with a focus on the platelet function analyser (PFA-100 and PFA-200). <i>Annals of Blood</i> , 0, 4, 3-3.	0.4	5
555	Analytical performance of the new D-dimer and antithrombin assay on Roche cobas t 711 analyzer. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e54-e56.	0.7	5
556	Assessment of Plasma Sample Quality on Siemens Atellica COAG 360 System. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 315-318.	1.5	5
557	Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 457-464.	1.5	5
558	Use of a novel platelet function analyzer (PFA-100, $\text{C}$ ) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders. <i>American Journal of Hematology</i> , 1999, 62, 165-174.	2.0	5



#	ARTICLE	IF	CITATIONS
559	A better approach to monitoring of therapy in von Willebrand disease?. Thrombosis and Haemostasis, 2008, 100, 371-373.	1.8	5
560	Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. Thrombosis and Haemostasis, 1989, 61, 217-24.	1.8	5
561	Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thrombosis and Haemostasis, 2000, 84, 541-7.	1.8	5
562	Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study. Frontiers in Medicine, 2022, 9, 796109.	1.2	5
563	More on: platelet function analyser (PFA)-100R closure time in the evaluation of platelet disorders and platelet function. Journal of Thrombosis and Haemostasis, 2006, 4, 2099-2100.	1.9	4
564	Hemophilia, cancer and cardiovascular disease. Blood Coagulation and Fibrinolysis, 2010, 21, 1-2.	0.5	4
565	Problems in laboratory testing - haemophilia and beyond. Journal of Thrombosis and Haemostasis, 2010, 8, 1119-20.	1.9	4
566	Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part III. Seminars in Thrombosis and Hemostasis, 2010, 36, 001-005.	1.5	4
567	Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2010, 36, 573-574.	1.5	4
568	The new and the old of heparin-induced thrombocytopenia. Clinical Chemistry and Laboratory Medicine, 2015, 53, 149-52.	1.4	4
569	Editorial Compilation V. Seminars in Thrombosis and Hemostasis, 2018, 44, 193-196.	1.5	4
570	Editorial Compilation VII. Seminars in Thrombosis and Hemostasis, 2019, 45, 429-432.	1.5	4
571	Commentary: Controversies in Thrombosis and Hemostasis Part 2â€“Does Sticky Platelet Syndrome Exist?. Seminars in Thrombosis and Hemostasis, 2019, 45, 069-072.	1.5	4
572	Vascular Disease and Dementia: Lipoprotein(a) as a Neglected Link. Seminars in Thrombosis and Hemostasis, 2019, 45, 544-547.	1.5	4
573	Troubleshooting an isolate prolongation of activated partial thromboplastin time in a patient with acute myocardial infarctionâ€“a paradigmatic case report. Annals of Translational Medicine, 2016, 4, 426-426.	0.7	4
574	The impact factor and journals in laboratory medicine. Clinical Laboratory, 2009, 55, 49-52.	0.2	4
575	A Simple, Whole Blood Method for Assessment of Platelet Function. Thrombosis Research, 1998, 90, 163-169.	0.8	3
576	A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1223-9.	1.4	3

#	ARTICLE	IF	CITATIONS
577	Identification, Pathogenesis, and Treatment of Factor Inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 719-722.	1.5	3
578	UNSUSPECTED COAGULOPATHY RARELY PREVENTS IV THROMBOLYSIS IN ACUTE ISCHEMIC STROKE. <i>Neurology</i> , 2010, 74, 1477-1478.	1.5	3
579	<i>Seminars in Thrombosis and Hemostasis</i> . Foreword. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 803-804.	1.5	3
580	Farewell to 2010!. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 797-802.	1.5	3
581	Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part VI. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 125-128.	1.5	3
582	Discard tube for coagulation testing. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 572-573.	0.5	3
583	Quality in Hemostasis and Thrombosis, Part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 229-232.	1.5	3
584	Quality in Hemostasis and Thrombosis â€” Part III. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 140-145.	1.5	3
585	Hot Topics VI. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 713-717.	1.5	3
586	â€œBleeding in the jungleâ€ American <i>Journal of Hematology</i> , 2015, 90, 843-846.	2.0	3
587	Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation. <i>Haemophilia</i> , 2018, 24, e148-e152.	1.0	3
588	Diagnosis and management of von Willebrand disease in Australia. <i>Annals of Blood</i> , 0, 3, 31-31.	0.4	3
589	Not as sweet as honey: A rare case of an apparent factor V â€œinhibitorâ€ in association with bee sting anaphylaxis. <i>American Journal of Hematology</i> , 2018, 93, 965-970.	2.0	3
590	The Model List of Essential In Vitro Diagnostics: nuisance or opportunity?. <i>Diagnosis</i> , 2019, 6, 187-188.	1.2	3
591	A diagnosis of von Willebrand disease despite normal test results for factor VIII and von Willebrand factor antigen and activity. <i>American Journal of Hematology</i> , 2019, 94, 1425-1432.	2.0	3
592	Welcome to <i>Seminars in Thrombosis and Hemostasis</i> 2019â€”New (2017) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 001-004.	1.5	3
593	Editorial Compilation VI. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 005-009.	1.5	3
594	Impact of low volume citrate tubes on results of firstâ€line hemostasis testing. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 472-477.	0.7	3

#	ARTICLE	IF	CITATIONS
595	An Update on Biological and Clinical Associations between E-Cigarettes and Myocardial Infarction. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 512-514.	1.5	3
596	The Pointy End of Point-of-Care Testing for Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2020, 120, 011-013.	1.8	3
597	2019 Eberhard F. Mammen Award Announcements: Part II – Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 105-113.	1.5	3
598	Plasma vs serum as test sample for the chemiluminescent AcuStar HemosIL HIT <sup>®</sup> PF4 <sup>®</sup> assay. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e41-e44.	0.7	3
599	Welcome to <i>Seminars in Thrombosis and Hemostasis</i> 2020 – New (2018) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 001-005.	1.5	3
600	Periodontal Disease and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 110-111.	1.5	3
601	Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 237-242.	0.5	3
602	New STH (2020) Impact Factor, Most Highly Cited Papers, and Other Journal Metrics. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 745-753.	1.5	3
603	Comparing the quality of testing for von Willebrand disease in different geographic localities. <i>Haemophilia</i> , 2022, 28, 193-196.	1.0	3
604	Pathology utilisation during COVID-19 outbreaks beyond viral testing: routine coagulation and D-dimer testing. <i>Pathology</i> , 2023, 55, 155-159.	0.3	3
605	Effect of overnight 4°C storage of whole blood on von Willebrand factor. <i>Transfusion</i> , 2006, 46, 1057-1059.	0.8	2
606	Standardization, Quality Assurance, and Emerging Diagnostic Technologies in Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 217-219.	1.5	2
607	Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 23-25.	0.5	2
608	Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: Only a part of the story. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1122-1123.	1.8	2
609	von Willebrand disease, type 2B: A diagnosis more elusive than previously thought. <i>Thrombosis and Haemostasis</i> , 2008, 99, 630-631.	1.8	2
610	Time to seek further clarity in the molecular analysis of von Willebrand disease?. <i>Thrombosis and Haemostasis</i> , 2009, 102, 175-177.	1.8	2
611	Farewell to 2009!. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 715-718.	1.5	2
612	Relationship between 24-h air pollution, emergency department admission and diagnosis of acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 381-386.	1.0	2

#	ARTICLE	IF	CITATIONS
613	Seminars in Thrombosis & Hemostasis 2010: Impact Factor and Highest-Cited Articles from 2008 to 2009. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 863-868.	1.5	2
614	New developments in the diagnosis and treatment of von Willebrand disease. <i>Clinical Investigation</i> , 2012, 2, 781-795.	0.0	2
615	Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1455-1458.	1.9	2
616	Hot Topics V. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 005-010.	1.5	2
617	Quality in Hemostasis and Thrombosis – Part IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 263-266.	1.5	2
618	Hot Topics VII. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 355-358.	1.5	2
619	Editorial Compilation – II. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 599-602.	1.5	2
620	2018 Eberhard F. Mammen Award Announcements: Part II – Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 123-129.	1.5	2
621	Understanding the extent of the diagnostic potential of coagulation factors. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 273-276.	1.5	2
622	Sample stability for routine coagulation testing. <i>Thrombosis Research</i> , 2020, 196, 130-134.	0.8	2
623	– Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendation from the women's SSC of the ISTH – Response to comment from Kitchen et al. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2420-2422.	1.9	2
624	Editorial Compilation VIII. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 393-397.	1.5	2
625	Editorial Compilation IX. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 006-010.	1.5	2
626	Machine learning and coagulation testing: the next big thing in hemostasis investigations?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1177-1179.	1.4	2
627	Effect of sample heat inactivation on test levels of HIT-IgG(PF4-H) detected by the ACL AcuStar. <i>Thrombosis Research</i> , 2021, 200, 12-15.	0.8	2
628	Preface to Special Issue: diagnosis and management of von Willebrand disease – diverse approaches to a global and common bleeding disorder. <i>Annals of Blood</i> , 0, 3, 43-43.	0.4	2
629	Flow Cytometric Detection of Procoagulant Properties of Plasma from Patients with Clinically Confirmed Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Blood</i> , 2021, 138, 3211-3211.	0.6	2
630	Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12689.	1.0	2

#	ARTICLE	IF	CITATIONS
631	2021 Eberhard F. Mammen Award Announcements: Part IIâ€”Young Investigator Awards. Seminars in Thrombosis and Hemostasis, 2022, 48, 265-273.	1.5	2
632	Is elevated factor VIII a risk factor for venous thromboembolism in Canada?. Thrombosis and Haemostasis, 2005, 94, 1112-1113.	1.8	1
633	Unrecognized pellagra masquerading as odynophagia. Internal Medicine Journal, 2006, 36, 472-474.	0.5	1
634	Increased Propensity to Bruising in Red-Haired Females: A Possible Role for von Willebrand Factor?. Anesthesia and Analgesia, 2006, 103, 1622-1623.	1.1	1
635	Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1â€”3?. Journal of Thrombosis and Haemostasis, 2008, 6, 545-546.	1.9	1
636	Welcome to <i>Seminars in Thrombosis and Hemostasis</i>-2008!. Seminars in Thrombosis and Hemostasis, 2008, 34, 001-002.	1.5	1
637	Hot Topics II: An Editorial Collection of Current Issues and Controversies in Thrombosis and Hemostasis. Seminars in Thrombosis and Hemostasis, 2008, 34, 003-006.	1.5	1
638	Salbutamol in Athletes. Clinical Journal of Sport Medicine, 2008, 18, 469.	0.9	1
639	Laboratory diagnostics and appropriate care of people with haemophilia. Haemophilia, 2011, 17, 824-825.	1.0	1
640	Assessment for antithrombin deficiency in the real world. International Journal of Laboratory Hematology, 2011, 33, 656-658.	0.7	1
641	Thrombocytopenic Platelet Disorders. Seminars in Thrombosis and Hemostasis, 2011, 37, 615-616.	1.5	1
642	Thrombotic and Hemorrhagic Syndromes Associated with Autoimmunity and Infection. Seminars in Thrombosis and Hemostasis, 2012, 38, 421-424.	1.5	1
643	Welcome to Seminars in Thrombosis & Hemostasis 2013. Seminars in Thrombosis and Hemostasis, 2013, 39, 005-009.	1.5	1
644	Editorial Compilation III. Seminars in Thrombosis and Hemostasis, 2017, 43, 004-007.	1.5	1
645	Myocardial Infarction, Unstable Angina, and White Thrombi: Time to Move Forward?. Seminars in Thrombosis and Hemostasis, 2019, 45, 115-116.	1.5	1
646	Impact of water temperature on reconstitution of quality controls for routine hemostasis testing. Diagnosis, 2021, 8, 233-238.	1.2	1
647	2B or not 2B? A diagnosis of von Willebrand disease a lifetime of 86 years in the making. Blood Coagulation and Fibrinolysis, 2021, 32, 229-233.	0.5	1
648	Welcome to Seminars in Thrombosis & Hemostasis 2021â€”New (2019) Impact Factor and Most Highly Cited Papers. Seminars in Thrombosis and Hemostasis, 2021, 47, 001-005.	1.5	1

#	ARTICLE	IF	CITATIONS
649	Hereditary Thrombophilias: Pathophysiology, Timing of Testing and Familial Testing. , 2016, , 475-484.		1
650	More on the Impact Factor and thrombosis and haemostasis journals: Benefits and limitations. Thrombosis and Haemostasis, 2007, 98, 475-476.	1.8	1
651	Editorial Compilation X. Seminars in Thrombosis and Hemostasis, 2021, 47, 754-758.	1.5	1
652	Urgent monitoring of dabigatran plasma levels: sometimes less is more. Polish Archives of Internal Medicine, 2014, 124, 639-640.	0.3	1
653	Management of hemolyzed specimens. Laboratornaya Sluzhba, 2017, 6, 38.	0.0	1
654	Thrombin generation in different commercial sodium citrate blood tubes. Journal of Medical Biochemistry, 2019, 39, 19-24.	0.7	1
655	Editorial Compilation XI. Seminars in Thrombosis and Hemostasis, 2022, 48, 127-131.	1.5	1
656	Getting smart with coagulation. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	1
657	âœVon Willebrand disease type 2M: Correlation between genotype and phenotypeâœ Comment from Favaloro. Journal of Thrombosis and Haemostasis, 2022, 20, 1019-1021.	1.9	1
658	Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone. American Journal of Hematology, 2002, 70, 330-331.	2.0	0
659	Professor Ronald A. Asherson, M.D. (Hon), F.R.C.P., M.D., F.A.C.P., F.C.P., F.A.C.R., Dip. O&G (Hon) [1934âœ2008]. Seminars in Thrombosis and Hemostasis, 2008, 34, 211-211.	1.5	0
660	Laboratory Evaluation of von Willebrand Disease: Phenotypic Analysis. , 2009, , 125-136.		0
661	Welcome to the First Issue of <i>Seminars in Thrombosis and Hemostasis</i> for 2009. Seminars in Thrombosis and Hemostasis, 2009, 35, 001-002.	1.5	0
662	Relationship between activated partial thromboplastin time, heparin and potassium levels. Diabetes Research and Clinical Practice, 2009, 83, e33-e34.	1.1	0
663	Genetic testing in von Willebrand disease: reply to rebuttal. Journal of Thrombosis and Haemostasis, 2010, 8, 861-862.	1.9	0
664	Global Hemostasis: New Approaches to Patient Diagnosis and Treatment Monitoring. Seminars in Thrombosis and Hemostasis, 2010, 36, 693-694.	1.5	0
665	Under-Recognized Significance of Endothelial Heterogeneity: Hemostasis, Thrombosis, and Beyond. Seminars in Thrombosis and Hemostasis, 2010, 36, 223-224.	1.5	0
666	Cycling: To Race or to Live âœ Reflections on Skewed Priorities?. International Journal of Sports Medicine, 2011, 32, 648-649.	0.8	0

#	ARTICLE	IF	CITATIONS
667	Hormones, Endocrine Disorders, and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 003-006.	1.5	0
668	Welcome to <i>Seminars in Thrombosis &amp; Hemostasis</i> 2012. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 05-06.	1.5	0
669	Artefactual "in vitro coagulopathy" in a patient with non-Hodgkin lymphoma and lower gastrointestinal bleeding. <i>Medical Journal of Australia</i> , 2014, 200, 293-294.	0.8	0
670	Articles from <i>Seminars in Thrombosis &amp; Hemostasis (STH) Archives</i> . <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, A1-A1.	1.5	0
671	A Tribute to Professor Jerry Koutts, MD (Syd), BS, FRACP, FRCPA (1944-2013). <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 001-004.	1.5	0
672	Articles from <i>Seminars in Thrombosis &amp; Hemostasis (STH) Archives: Part II</i> . <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, A1-A2.	1.5	0
673	Welcome to <i>Seminars in Thrombosis &amp; Hemostasis</i> 2014. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 011-016.	1.5	0
674	Effect of contaminant 0.9% saline on tests of haemostasis. <i>Anaesthesia</i> , 2015, 70, 1001-1002.	1.8	0
675	Commentary. <i>Clinical Chemistry</i> , 2015, 61, 912-912.	1.5	0
676	Welcome to <i>Seminars in Thrombosis &amp; Hemostasis</i> 2015: New (2013) Impact Factor and Most Highly Cited Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 001-006.	1.5	0
677	Welcome to <i>Seminars in Thrombosis &amp; Hemostasis</i> 2016: New (2014) Impact Factor and Most Highly Cited Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 001-004.	1.5	0
678	Welcome to <i>Seminars in Thrombosis &amp; Hemostasis</i> 2017 " New (2015) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 001-003.	1.5	0
679	2B or not 2B? A prothrombotic tendency masquerading as a bleeding disorder. <i>American Journal of Hematology</i> , 2017, 92, 584-590.	2.0	0
680	Editorial Compilation IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 549-552.	1.5	0
681	Welcome to <i>Seminars in Thrombosis &amp; Hemostasis</i> 2018. New (2016) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 001-004.	1.5	0
682	Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 95-100.	1.4	0
683	45 years of <i>Seminars in Thrombosis and Hemostasis</i> . <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 407-416.	1.5	0
684	Mathematical rounding as a post-analytical issue in pathology reporting: generation of bias in INR resulting. <i>Pathology</i> , 2018, 50, 459-461.	0.3	0

#	ARTICLE	IF	CITATIONS
685	A holistic approach for the diagnosis of venous thromboembolism. <i>Journal of Laboratory and Precision Medicine</i> , 2020, 5, 20-20.	1.1	0
686	A retrospective analysis of correlation between APTT and anti-XA levels using ex vivo Plasma samples from patients on intravenous heparin therapy. <i>Pathology</i> , 2020, 52, S115.	0.3	0
687	Unfractionated heparin monitoring with activated partial thromboplastin time. <i>Pathology</i> , 2020, 52, S36.	0.3	0
688	More or less living according to your blood type. <i>Blood Transfusion</i> , 2015, 13, 351-3.	0.3	0
689	Borrowing (once again) from the animal kingdom. <i>Blood Transfusion</i> , 2017, 15, 294-295.	0.3	0
690	Welcome to Seminars in Thrombosis & Hemostasis 2022. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 001-002.	1.5	0
691	Platelet function testing: auditing local practice and broader implications. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2010, 23, 21-31.	0.1	0
692	Improving the inter-laboratory harmonization of the international normalized ratio (INR): utilizing the concept of transference to estimate and/or validate international sensitivity index (ISI) and mean normal prothrombin time (MNPT) values and/or to eliminate measurement bias. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2012, 25, 13-25.	0.1	0